Further, despite the release of a variety of cytokine (e.g., IFN-γ, perforin and granzyme B) and cytotoxicity induced by EpCAM-specific CAR-NK-92 cells against EpCAM-positive CRC cells in vitro, synergistic influences of multi-kinase inhibitor regorafenib and modified CAR-NK-92 cells were supported in a murine model with human CRC xenografts. Here, EPCAM is linked to colorectal carcinoma.